Author

R. Brough

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Assay:DNA methylation· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

C. J. Lord· 3 shared S. J. Pettitt· 3 shared A. Ashworth· 2 shared A. Gulati· 2 shared D. B. Krastev· 2 shared F. Song· 2 shared A. Drean· 1 shared A. J. Todd· 1 shared

Activity by Year

2017-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. J. Lord

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality

J. C.-Y. Tien, Y. Chang, Y. Zhang, J. Chou, Y. Cheng, X. Wang, J. Yang, R. Mannan, P. Shah, X.-M. Wang, A. J. Todd, S. Eyunni, C. Cheng, R. J. Rebernick, L. Xiao, , A. M. Chinnaiyan

This study shows CDK12 loss drives prostate cancer development and identifies CDK13 as a therapeutic target through paralog-based synthetic lethality in CDK12-mutant tumors.

bioRxiv · Mar 20, 2024Cancer Biology

MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells

A. Zelceski, P. Francica, L. Lingg, M. Mutlu, C. Stok, M. Liptay, J. Alexander, J. S. Baxter, R. Brough, A. Gulati, S. Haider, M. Raghunandan, F. Song, S. Sridhar, J. V. Forment, , C. J. Lord

This study shows that PSMC3IP and MND1 depletion increases PARP inhibitor sensitivity in mitotic cells through impaired D-loop formation and homology-directed repair.

bioRxiv · Aug 24, 2022Cancer Biology

Targeting DNA damage response and Replication Stress in Pancreatic Cancer

S. Dreyer, R. Upstill-Goddard, V. Paulus-Hock, C. Paris, E. Maria-Lampraki, E. Dray, B. Serrels, S. Rebus, H. Brunton, C. Nourse, U.-M. Bailey, M. Jones, K. Moran-Jones, D. Wright, F. Duthie, , Lord

The paper identifies novel therapeutic strategies for pancreatic cancer by analyzing DNA damage response and replication stress in patient-derived cell lines.

bioRxiv · Jul 24, 2019Cancer Biology

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

S. J. Pettitt, D. B. Krastev, I. Brandsma, A. Drean, F. Song, R. Aleksandrov, M. I. Harrell, M. Menon, R. Brough, J. Campbell, J. Frankum, M. Ranes, H. N. Pemberton, R. Rafiq, K. Fenwick, , C. J. Lord

The paper identifies PARP1 point mutations causing PARP inhibitor resistance through CRISPR-Cas9 screens and shows their impact on PARP1 trapping and chemotherapy sensitivity.

bioRxiv · Oct 14, 2017Cancer Biology